

Article

Differential Activation of *TAS2R4* May Recover Ability to Taste Propylthiouracil for Some *TAS2R38* AVI Homozygotes

Alissa A. Nolden ^{1,2,3} , Maik Behrens ^{4,5} , John E. McGeary ^{6,7}, Wolfgang Meyerhof ^{4,8} and John E. Hayes ^{2,3,*} 

- ¹ Department of Food Science, University of Massachusetts, Amherst, MA 01003, USA; anolden@umass.edu
² Sensory Evaluation Center, The Pennsylvania State University, University Park, PA 16802, USA
³ Department of Food Science, The Pennsylvania State University, University Park, PA 16802, USA
⁴ German Institute of Human Nutrition Potsdam-Rehbruecke, Department Molecular Genetics, 14558 Nuthetal, Germany; m.behrens.leibniz-lsb@tum.de (M.B.); wolfgang.meyerhof@uks.eu (W.M.)
⁵ Leibniz Institute for Food Systems Biology, Technical University of Munich, 85354 Freising, Germany
⁶ Center of Innovation in Long Term Services & Supports, VA Providence Healthcare, Providence, RI 02908, USA; john.mcgeary@brown.edu
⁷ Department of Psychiatry & Human Behavior, Alpert Medical School of Brown University, Providence, RI 02903, USA
⁸ Center for Integrative Physiology and Molecular Medicine, Saarland University, 66424 Homburg, Germany
* Correspondence: jeh40@psu.edu

Abstract: Bitterness from phenylthiocarbamide and 6-n-propylthiouracil (PROP) varies with polymorphisms in the *TAS2R38* gene. Three SNPs form two common (AVI, PAV) and four rare haplotypes (AAI, AAV, PVI, and PAI). AVI homozygotes exhibit higher detection thresholds and lower suprathreshold bitterness for PROP compared to PAV homozygotes and heterozygotes, and these differences may influence alcohol and vegetable intake. Within a diplotype, substantial variation in suprathreshold bitterness persists, and some AVI homozygotes report moderate bitterness at high concentrations. A second receptor encoded by a gene containing a functional polymorphism may explain this. Early work has suggested that PROP might activate *TAS2R4* in vitro, but later work did not replicate this. Here, we identify three *TAS2R4* SNPs that result in three diplotypes—SLN/SLN, FVS/SLN, and FVS/FVS—which make up 25.1%, 44.9%, and 23.9% of our sample. These *TAS2R4* haplotypes show minimal linkage disequilibrium with *TAS2R38*, so we examined the suprathreshold bitterness as a function of both. The participants ($n = 243$) rated five PROP concentrations in duplicate, interleaved with other stimuli. As expected, the *TAS2R38* haplotypes explained ~29% ($p < 0.0001$) of the variation in the bitterness ratings, with substantial variation within the haplotypes (AVI/AVI, PAV/AVI, and PAV/PAV). Notably, the *TAS2R4* diplotypes (independent of the *TAS2R38* haplotypes) explained ~7–8% of the variation in the bitterness ratings ($p = 0.0001$). Given this, we revisited if PROP could activate heterologously expressed *TAS2R4* in HEK293T cells, and calcium imaging indicated 3 mM PROP is a weak *TAS2R4* agonist. In sum, our data are consistent with the second receptor hypothesis and may explain the recovery of the PROP tasting phenotype in some AVI homozygotes; further, this finding may potentially help explain the conflicting results on the *TAS2R38* diplotype and food intake.

Keywords: propylthiouracil; phenylthiocarbamide; individual differences; supertasting; suprathreshold; psychophysics; genetic variation



Citation: Nolden, A.A.; Behrens, M.; McGeary, J.E.; Meyerhof, W.; Hayes, J.E. Differential Activation of *TAS2R4* May Recover Ability to Taste Propylthiouracil for Some *TAS2R38* AVI Homozygotes. *Nutrients* **2024**, *16*, 1357. <https://doi.org/10.3390/nu16091357>

Academic Editors: Iole Tomassini Barbarossa and Melania Melis

Received: 28 March 2024

Revised: 24 April 2024

Accepted: 25 April 2024

Published: 30 April 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Bitterness is classically framed as an evolutionary mechanism to defend against the ingestion of toxins found in plants [1–3], with the caveat that many bitter stimuli are not toxic [4,5]. To detect a wide range of structurally diverse bitter compounds, humans have numerous bitter taste receptors (*TAS2Rs*) encoded by ~26 functional genes (*TAS2Rs*) [6,7]. Given modern food safety regulatory regimes, we no longer rely on this defense mechanism

for survival, and the view that bitter equals bad is an oversimplification [8,9]. Many compounds in the human diet elicit bitterness (e.g., [10,11]), and bitter foods (e.g., grapefruit, chocolate, beer) are widely consumed and enjoyed across various cultures and cuisines. To activate bitter receptors, a ligand must fit into a binding pocket formed by a specific amino acid sequence in conserved regions of the receptor protein. Yet, the ~26 human bitter genes also show a large amount of genetic variation [12]. Changing an individual nucleotide within the protein coding sequence (a single nucleotide polymorphism; SNP) can lead to a change in the amino acid for the affected codon (i.e., a missense mutation). Numerous *TAS2R* SNPs have been shown to influence receptor activation in vitro (e.g., [13–17]), and these SNPs can predict bitterness, and the liking or intake of bitter compounds, foods, and beverages (e.g., [11,13,16–25]). Specifically, *TAS2R* SNPs have been associated with differential bitterness of, liking for, or intake of foods, including sweetened foods [26,27], non-nutritive sweeteners [21,28], refined cereals [29], alcohol [11,19,30–33], and vegetables [20,33–37]. Not all reports agree (e.g., [38–41]), but on balance, systematic reviews support a link between *TAS2R* variation and food preferences [42,43].

Variation in the ability to taste bitterness was first observed for phenylthiocarbamide (PTC) by Fox in the early 1930s [44,45], and attempts to link such individual differences to food preferences and dietary habits date back to the early 1960s [46–48]. Individuals with an ability to sense bitterness at low concentrations of PTC were identified as ‘tasters’, while those perceiving no taste were considered ‘nontasters’. Originally, it was hypothesized this trait was the result of a simple Mendelian trait [49,50], although modern work considers it a quantitative trait [51,52]. Following the advent of the human genome project, Kim and colleagues [12,22] were able to identify three single nucleotide polymorphisms (SNPs) in *TAS2R38* (chr. 7) that could explain the variation in the detection thresholds for PTC. These three SNPs, located at positions 49, 262, and 296, were shown to be in linkage disequilibrium, creating two common haplotypes. Thus, when dichotomized into groups based on thresholds, the ‘taster’ haplotype consists of Pro49, Ala262, and Val296, commonly abbreviated as PAV, while the ‘nontaster’ haplotype, Ala49, Val262, and Ile296, is abbreviated as AVI. Other rare haplotypes exist but reports on these [15,53–55] are largely inconclusive, due to the small sample sizes. The vast majority of AVI homozygotes show greatly elevated detection thresholds [56], but it is notable that some do not [53,55]. Typically, heterozygotes have lower thresholds (i.e., greater sensitivity), similar to those seen for PAV homozygotes (e.g., Figure 1 in [53]). Critically, detection thresholds are not the only taste phenotype that has been measured for bitterness, as many reports have also shown large differences in suprathreshold responses (e.g., [20,53,57,58]). Thus, these two distinct taste phenotypes—detection thresholds and rated intensity—are related but not redundant [53,59]. Here, we focus on suprathreshold intensities, not detection thresholds.

Definitionally, SNPs are variants in nucleotide sequence that may or may not result in amino acid changes in various regions of the receptor. Here, for convenience, we define a functional SNP as a polymorphism that has been shown to explain perceptual variation in vivo; critically, however, a functional SNP may not be the causal SNP that directly affects receptor binding or activation. That is, a functional SNP in vivo may act as a proxy for a mechanistically causal SNP due to linkage disequilibrium with the causal SNP. Specifically, a causal SNP could be located in different regions of the receptor, the extracellular or intracellular loops or the transmembrane domains (TM1–7), or even on another nearby gene (i.e., a long-range haplotype). For example, multiple early gene association studies suggested the Arg299Cys SNP (rs10772420) in *TAS2R19* was functional [11,24], but subsequent work strongly suggested that the causal SNP was actually located in a nearby gene, *TAS2R31* [60]. Returning to *TAS2R38*, the dominant causal SNPs appear to be at amino acid positions 49 (intracellular loop 1) and 262 (TM6). Specifically, Bufe and colleagues [15] demonstrated the functional importance of each position by expressing the *TAS2R38* variants AVI, AVV, PAV, and PVI in HEK293 cells. They found PAV and PVI had similar responses to PROP and PTC, whereas AVI and AVV exhibited no response. This suggests the amino acids located at position 49 and 262 are responsible for *TAS2R38* receptor function [15]. For *TAS2R9*,

Dotson et al. [14] reported that an allele at amino acid position 187, located in the TM5 domain, was critical for activation in vitro. SNPs in the extracellular loops of *TAS2R43* and *TAS2R30* may alter function by interfering with the binding pocket, while variation in the intracellular loops may interfere with signaling pathways [16].

Multiple studies have shown PTC and PROP activate *TAS2R38* in vitro [6,15,54,55]. Notably, there is some evidence that PROP also activates *TAS2R4* [61], with the caveat that the concentration of PROP used (10mM) was well above the human detection threshold and that *TAS2R4* would not be activated at the concentrations typically presented when determining the threshold sensitivity or suprathreshold response [62]. Subsequent studies have found evidence that *TAS2R4* responds to other bitter compounds in vitro including denatonium benzoate, peptides, and (-)-epicatechin [6,61,63–65].

Ueda and colleagues identified multiple polymorphisms in the *TAS2R4* sequence at nucleotide positions 20 (T or C), 221 (C or T), 286 (G or C), and 512 (G or A). These SNPs code for the Phe7Ser, Thr74Met, Val96Leu, and Ser171Asn alleles. Subsequently, Hayes et al. [11] observed strong linkage disequilibrium (LD) across four SNPs in *TAS2R3*, -4, and -5, at nucleotide position 45 (T or C) in *TAS2R3*, position 286 (G or C) in *TAS2R4*, and position 55 (A or G) and position 77 (G or T) in *TAS2R5*. Notably, the *TAS2R3/4/5* diplotype explained the perceived bitterness of sampled instant espresso coffee, with individuals with one or two copies of the TGAG haplotype experiencing greater bitterness than CCGT/CCGT individuals. Elsewhere, Risso et al. showed the rs2234001 SNP in *TAS2R4* explains the variable bitterness of stevioside [66], a natural compound found in the stevia plant. Collectively, these data suggest that the activation of *TAS2R4* that varies with the *TAS2R4* genotype could potentially explain the additional variation in the psychophysical response to PROP in humans.

Here, we extend prior work by showing that three SNPs in *TAS2R4* explain the phenotypic variation in the bitterness of PROP in vivo and do so independently from the *TAS2R38* genotype. Separately, we also show PROP is a weak *TAS2R4* agonist in vitro at concentrations relevant to human taste perception.

2. Materials and Methods

2.1. Overview

Data presented here were part of a large laboratory-based study with up to four test sessions, each at least one week apart. Data collected on the first day of testing are reported here; sessions 2, 3, and 4 are described elsewhere [21,67]. At the beginning of session 1, the entire study was explained to participants and written informed consent was obtained (details below). The first task was completion of a food preference questionnaire. Next, anthropometrics and salivary DNA samples were collected, followed by digital microscopy of the anterior tongue. Verbal orientation to the intensity scale was given next, including rating 15 imagined or remembered sensations [68] as a warmup task. Participants then sampled six tastants and irritants, rating them for multiple qualities. The last task in session 1 was to complete a standard propylthiouracil phenotyping protocol (details below). After the session ended, they were emailed an online survey with multiple personality measures. Total time in the laboratory for session 1 was ~1 h, and all data were collected one-on-one with project staff.

2.2. Participants

A prescreen was completed by each participant before the first session to ensure that they met the study's qualification criteria. Eligibility criteria included age between 18–45 years old; not pregnant or breastfeeding; non-smoker (had not smoked in the last 30 days); no known defects of smell or taste; no lip, cheek, or tongue piercings; no history of any condition involving chronic pain; not currently taking any prescription pain medication; no reported history of choking or difficulty swallowing; and no history of thyroid disease. Participants also needed to be willing to provide a DNA sample via saliva.

Here, we report data from 243 participants (97 men) with a mean age of 25.8 ± 0.46 . Race and ethnicity were self-reported using relevant guidelines provided by the United States 1997 OMB Directive 15 guidelines; a majority of the participants were of European ancestry ($n = 171$), with others reporting Asian ($n = 33$) or African American ($n = 6$) ancestry.

2.3. Ethics Statement

Written informed consent was obtained from all participants. All procedures were approved by the Pennsylvania State University Institutional Review Board (protocol number #33176), in accordance with the Helsinki Declaration of 1975.

2.4. Food Preference, Anthropometrics, and Tongue Microscopy

Following written consent, participants were given a brief set of verbal instructions on scale use before completing a 63-item hedonic survey of foods, beverages, and non-food items using an unstructured generalized hedonic scale. Anthropometric measurements (height, weight, percent body fat, and resting blood pressure) were also taken. Digital still photographs of the anterior tongue were also obtained. These data are not used here and are reported elsewhere.

2.5. Psychophysical Scaling of Oral and Non-Oral Stimuli

Perceived intensities of suprathreshold stimuli were measured using a generalized Labeled Magnitude Scale (gLMS) [69]. All participants were given a verbal explanation of the scale, and then practiced using the scale, which included making ratings of 15 remembered or imagined sensations [68]. All psychophysical and hedonic data were collected using Compusense five, version 5.2 (Compusense, Inc., Guelph, ON, Canada).

Participants rated a standard assessment battery of 6-n-propylthiouracil (PROP), sodium chloride (salt), and 1-kHz tones, as described previously (e.g., [11,19]). Five levels of salt and PROP were rated in duplicate, and blocks of 5 tones were repeated five times (25 in total). Stimuli were presented randomly within a block, and blocks were presented in a fixed order: 5 tones, 5 salt solutions, 5 tones, 5 salt solutions, 5 tones, 5 PROP solutions, 5 tones, 5 PROP solutions, and 5 tones. Solutions were prepared in half log steps (3.2, 1, 0.32, 0.1, 0.032 mM for PROP, and 1, 0.32, 0.1, 0.032, and 0.01 M for salt). The 1-kHz tones were presented using a calibrated Maico MA39 audiometer that had been modified to play the tones in both ears simultaneously; 1-kHz tones ranged from 50 to 90 dB in 10 dB steps. PROP and salt concentrations were prepared with USP-grade 6-n-propylthiouracil (Sigma, St Louis, MO, USA) and kosher salt in reverse osmosis (RO) water. Between each sample, participants rinsed with RO water, waiting a minimum of 30s before next sample, longer if the sensation was lingering. Overall intensity ratings for PROP were used as continuous variables rather than being binned into trichotomous groups (see [70] for rationale).

2.6. Participant Genotyping

DNA was collected from saliva, using Oragene collection kits according to manufacturer instructions (DNA Genotek Inc., Ottawa ON, Canada). SNPs (single nucleotide polymorphisms) in *TAS2R4* (chr 7: rs2233998 (Phe7Ser), rs2234001 (Val96Leu), rs2234002 (Ser171Asn)) and *TAS2R38* (chr 7: rs713598 (Ala49Pro), rs1726866 (Val262Ala), rs10246939 (Ile296Val)) were determined using Sequenom MassARRAY technology (Sequenom, San Diego, CA, USA) and taqman. Primers were purchased from Integrated DNA Technologies (Coralville, IA, USA). Genotypes were assigned automatically via MassARRAY software (Sequenom) and inspected by two technicians. To ensure accuracy, 15% of the samples were randomly selected and subjected to a secondary analysis. These SNP genotype frequencies did not vary from Hardy–Weinberg equilibrium: *TAS2R4* (rs2233998 ($p = 0.42$), rs2234001 ($p = 0.74$), rs2234002 ($p = 0.78$)) and *TAS2R38* (rs10246939 ($p = 0.33$), rs1726866 ($p = 0.20$), rs713598 ($p = 0.17$)).

2.7. In Vitro Functional Calcium Imaging Analyses

Two cDNA clones corresponding to the most frequently occurring TAS2R4 haplotype, CCA, and the second most observed haplotype, TGG, were cloned by PCR from genomic DNA and inserted into the vector pEAK10, which was modified to result in the addition of an amino terminal sst3 export tag and a carboxyl terminal addition of a herpes simplex virus glycoprotein D epitope (hsv-tag) to the coding region of the receptor [65]. The amino acid sequence of haplotype CCA exhibits a serine in position 7, a leucine residue in position 96, and an asparagine residue in position 171, whereas haplotype TGG shows phenylalanine, valine, and serine, respectively, in the corresponding positions. Accordingly, S₇L₉₆N₁₇₁ (SLN) corresponds to the CCA haplotype, while F₇V₉₆S₁₇₁ (FVS) corresponds to the TGG haplotype.

HEK 293T-cells stably expressing the chimeric G protein, G α 16-Gust44, were grown in 96-well plates and transiently transfected with TAS2R4 cDNA using Lipofectamine 2000 as described before [65]. For negative controls, the empty pEAK10 vector was used (=mock). After transient transfection, the cells were allowed to express the receptor for ~24 h, before they were subjected to calcium imaging analyses. The cells were loaded with the calcium-sensitive dye Fluo-4 AM in the presence of 2.5 mM probenecid. After washing the cells with C1 buffer (130 mM NaCl, 5 mM KCl, 2 mM CaCl₂, 10 mM glucose, 10 mM HEPES; pH 7.4), the plates were transferred into a fluorometric imaging plate reader (FLIPR Tetra, Molecular Devices, San Jose, CA, USA) and serial dilutions of 6-n-propylthiouracil in C1 buffer were automatically applied to the cells. Changes in intracellular calcium ions were monitored at a wavelength of 510 nm (488 nm excitation wavelength). Data of at least two independent experiments performed in triplicate were obtained and used for the calculation of dose–response relations. After subtraction of fluorescence changes observed in mock-transfected cells and normalization to background fluorescence, the average signal amplitudes were plotted against the logarithmic PROP concentrations using the function $f(x) = [a - d / (1 + (x/EC_{50})^{nH}) + d]$, with a = maximum, d = minimum, x = substance concentration, EC_{50} = half-maximal effective concentration, nH = –hillslope. Graphs were generated using SigmaPlot 12 (San Jose, CA, USA).

2.8. Statistical Analysis

Psychophysical data were analyzed using SAS 9.2 (SAS Institute, Cary, NC, USA). For individual gene analyses, analysis of variance (ANOVA) was performed via *proc mixed*. Post hoc comparisons were made via the Tukey–Kramer method. Association between polymorphisms was measured using r -squared values generated using Haploview. For TAS2R38 and TAS2R4, haplotypes were determined using PHASE and individuals with probabilities less than 0.8 were relabeled as missing for that haplotype, as individuals that had at least one complete haplotype could be used in individual haplotype analyses. Relative fluorescence changes in cells transfected with TAS2R4 constructs and negative (mock) control monitored for each PROP concentration were compared by ANOVA followed by a contrast test with an alpha risk level adjusted by Bonferroni multiple testing correction using IBM SPSS Statistics for Windows, version 20.0 (Armonk, NY, USA).

3. Results

3.1. TAS2R4 and TAS2R38 Haplotypes

In our cohort, we genotyped individuals for three SNPs in TAS2R38 (Table 1) as well as three SNPs in TAS2R4 (Table 2: F7S, V96L, and S171N). These SNPs are all located in a small region of chromosome 7. In our sample, we saw strong linkage disequilibrium between the three SNPs in TAS2R4, forming a haplotype based on solid spline LD (Figure 1). Additionally, three alleles, A49P, V262A, and I296V, in TAS2R38 also exhibited linkage with each other, consistent with previous reports (e.g., [22]). There was minimal evidence of an association between the individual SNPs in TAS2R4 and TAS2R38. This analysis was performed with the total cohort ($n = 243$). To ensure that ancestry did not alter the associations reported here, a secondary analysis was performed with only individuals

who reported Caucasian ancestry ($n = 171$). In this secondary analysis, the patterns of association did not change for the *TAS2R4* and *TAS2R38* haplotypes when comparing the total sample or the Caucasian-only subsample; therefore, all of the subsequent analyses are reported for the total cohort.

Table 1. Summary demographics and diplotypes of study participants.

Diplotype	<i>n</i> (%)	Asian	African American	White/Caucasian	Male/Female
PAV/PAV	48 (19.8%)	14	3	24	24/24
PAV/AVI	119 (49.0%)	9	2	90	46/73
AVI/AVI	51 (21.0%)	9	-	37	17/34
Rare	25 (10.3%)	1	1	20	10/15
Total	243	33	6	171	97/148

Table 2. *TAS2R4* SNPs and counts in the study participants.

rs2233998	rs2234001	rs2234002	Frequency (%)
S/F	L/V	N/S	109 (44.9%)
S/S	L/L	N/N	61 (25.1%)
F/S	V/V	S/S	58 (23.9%)




Figure 1. LD plot generated by Haploview with R^2 values representing values and shading, consisting of 8 SNPs from 4 different *TAS2Rs* on chromosome 7. Haplotype blocks were defined by solid spine of LD. Block 1 shows strong LD with 3 SNPs from *TAS2R4*. Block 2 shows association between two SNPs in *TAS2R38* (A49P, V262A, and I296V).

3.2. *TAS2R4* Diplotype Explains Variation in PROP Bitterness

In our cohort, nine different haplotypes were observed for *TAS2R4*. The most frequently occurring haplotype, SLN, exhibited a frequency of 240, compared to the second most observed haplotype, FVS, with a frequency of 233. Other haplotypes were observed at a lower frequency (n): FLN (10), FLS (3), FVN, and SVS (1). As would be expected from

these frequencies, the three most common diplotypes were SLN homozygotes (25.1%), FVS homozygotes (23.9%), and SLN/FVS heterozygotes (44.9%) (see Table 2). Accordingly, only individuals exhibiting these three most common *TAS2R4* diplotypes were used in the analysis between the *TAS2R4* diplotypes and PROP phenotype.

The repeated measures ANOVA revealed that the *TAS2R4* diplotype was significantly associated with the gLMS intensity ratings [$F(32,936) = 1.96$; $p = 0.001$] across all five concentrations of PROP, 0.032, 0.1, 0.32, 1.0, and 3.2 mM, as shown in Figure 2. The *TAS2R4* diplotype explained 7.7% of the variation for the highest concentration of PROP (3.2 mM) [$F(1,206) = 17.20$; $p < 0.0001$]. At the highest concentration, the FVS homozygotes rated bitterness significantly less than the SLN homozygotes or the heterozygotes, who did not differ from each other. At the second highest concentration, only the homozygous groups differed from each other.




Figure 2. Repeated measures ANOVA reveals that reported bitterness for PROP concentrations (0.032, 0.1, 0.32, 1.0, and 3.2 mM) were significantly associated with *TAS2R4* diplotype.

3.3. *TAS2R38* Explains Variation in PROP Bitterness

Consistent with previous literature, the *TAS2R38* diplotype was a significant predictor of PROP bitterness. In our cohort, the *TAS2R38* diplotype explained 29.3% of the variation in the perceived bitterness for 3.2mM PROP [$F(1,216) = 89.4$ $p < 0.0001$]. The repeated measures ANOVA across all five concentrations (Figure 3) revealed that the *TAS2R38* diplotype was a significant predictor [$F(8,860) = 33.96$ $p < 0.0001$]. At the three highest concentrations, all three groups were significantly different from each other, as expected from prior work.




Figure 3. Repeated measures ANOVA reveals that reported bitterness for PROP concentrations (0.032, 0.1, 0.32, 1.0, and 3.2 mM) were significantly associated with *TAS2R38* diplotype.

3.4. Combined Effects of *TAS2R38* and *TAS2R4* Diplotypes on Variation in PROP Bitterness

To determine the combined effects of the *TAS2R4* and *TAS2R38* diplotypes on the PROP ratings, all 207 individuals with common genotypes for both were assigned a polygenic bitterness score. The scores were assigned based on the number of higher-functioning alleles (e.g., 0, 1 or 2) for each receptor (similar to [54]), giving a minimum score of 0 (i.e., AVI/AVI and FVS/FVS individuals) and a maximum score of 4 (i.e., PAV/PAV and SLN/SLN individuals). Additional details on these scores are shown in Table 3.

Table 3. Polygenic bitterness score based on *TAS2R38* and *TAS2R4* diplotypes.

Score	n	Contributing Groups (n)
0	26	AVI/AVI + FVS/FVS
1	39	AVI/AVI + FVS/SLN (16) PAV/AVI + FVS/FVS (23)
2	79	AVI/AVI + SLN/SLN (4) PAV/AVI + FVS/SLN (71) PAV/PAV + FVS/FVS (4)
3	36	PAV/AVI + SLN/SLN (22) PAV/PAV + FVS/SLN (14)
4	27	PAV/PAV + SLN/SLN

The ANOVA revealed that the polygenic bitterness score based on the presumed functional *TAS2R4* and *TAS2R38* diplotypes significantly explained the variation in the bitterness ratings [$F(4,202) = 15.35, p < 0.0001$]. The mean ratings for the 26 individuals homozygous for both of the low-functioning haplotypes (dual AVI and FVS homozygotes) had a mean rating of 18.4 (± 3.9) compared to a mean of 56.8 (± 3.9) for the 27 individuals homozygous

for both of the high-functioning haplotypes (dual PAV and SLN homozygotes)—a ~3.1 fold difference.

3.5. *TAS2R4* Responds to High Concentrations of PROP In Vitro

Given the association between the *TAS2R4* genotype and PROP intensity ratings seen here, as well as the conflicting evidence in the literature concerning *TAS2R4* as a low-affinity PROP receptor, we re-evaluated *TAS2R4* responsiveness to PROP via functional heterologous expression assays. Accordingly, we transiently transfected HEK 293T-G α 16gust44 cells with cDNA constructs corresponding to the frequent haplotypes *TAS2R4*-SLN and *TAS2R4*-FVS. The stimulation of the transfected cells with increasing concentrations of PROP confirmed that the two *TAS2R4* variants responded to the compound with an elevation in the intracellular calcium levels (Figure 4). At a concentration of 100 μ M PROP, both variants exhibited significantly higher increases in fluorescence signals than the cells expressing the empty vector (negative control). At higher PROP concentrations, we observed a dose-dependent increase in the signal amplitudes for the cells transfected with the constructs confirming *TAS2R4* as a PROP receptor. The pronounced receptor-independent signals occurring at concentrations higher than 1 mM PROP prevented us from monitoring the fluorescent changes at higher concentrations. Comparing the PROP-induced activation among the two *TAS2R4* constructs, we observed only a slightly elevated responsiveness of *TAS2R4*-SLN with respect to *TAS2R4*-FVS, which did not reach statistical significance. Nonetheless, the effect was in the same direction as would be expected from the in vivo data, and the *TAS2R4*-SLN signals were consistently higher than the *TAS2R4*-FVS signals.




Figure 4. Functional calcium imaging analyses demonstrate PROP responsiveness of *TAS2R4* variants. (A) Dose–response relationships of *TAS2R4* haplotypes CCA (*TAS2R4*-SLN) and TGG (*TAS2R4*-FVS). Y-axis, relative change in fluorescence ($\Delta F/F$), x-axis log PROP concentration in mM. (B) Calcium traces elicited by 1mM PROP on cells transfected with *TAS2R4*-SLN, *TAS2R4*-FVS, or empty vector. The arrow indicates the time point of stimulus application. Scale: y-axis, 100 relative fluorescence units; x-axis, 2 min.

4. Discussion

Through use of in vitro testing in functional expression systems, ligands have been identified for most of the 26 known human bitter taste receptors. In 2001, Chandrashekar [61] identified *TAS2R4* as a potential receptor for PROP; however, subsequent work failed to replicate this finding [6]. Here, we show that PROP activates *TAS2R4* in vitro. Previously, three polymorphisms in *TAS2R38* have been shown to influence receptor activation in vitro and perception in vivo for PTC and [22] and PROP [15,53–55].

If *TAS2R38* were the sole receptor for PROP, and the AVI variant were nonfunctional (see [71]), then we would expect that the AVI homozygotes would not perceive any bitterness from PROP. However, the present data, as well as prior reports [15,19,53,54,72], suggest that some AVI homozygous individuals report bitterness at higher PROP concentrations (see Figure 3), suggesting PROP may activate additional receptors at higher concentrations.

To test this hypothesis, we considered *TAS2R4* as a candidate second receptor, since Chandrashekar and colleagues reported *TAS2R4* is activated by PROP [61]. Previously, in an early pilot study that predated the identification of the functional *TAS2R38* polymorphisms, Reed and colleagues [73] concluded that the *TAS2R3*, *TAS2R4*, and *TAS2R5* (chromosome 7) genotypes did not differ between the PROP-insensitive and -sensitive individuals. Eighteen individuals were genotyped for three SNPs in *TAS2R3* and *TAS2R4* and one SNP in *TAS2R5*. However, this unpublished abstract does not state how the PROP phenotype was determined, and it seems likely this null finding may be a false negative due to its insufficient power with just 18 participants. Based on other work focusing on coffee bitterness, we had reason to believe *TAS2R4* might contain functional SNPs, given other data associating such SNPs with differential bitterness from coffee [11] and stevia extracts [66].

Here, we confirm that PROP activates *TAS2R4* in vitro. Further, we show that polymorphisms in *TAS2R4* associate with the variation in the perceived bitterness of PROP in vivo. The response of *TAS2R38* to 1 μ M PROP in a functional expression system [54] has a similar response amplitude as *TAS2R4*. Still, the differential PROP response between the two *TAS2R4* variants (SLN and FVS) did not reach significance in vitro. This suggests that the causal SNP altering the function of *TAS2R4* may not be one of the SNPs in our analysis. However, because the amino acids at positions 7, 96, and 171 appear to explain the variation in PROP bitterness in vivo and *TAS2R4* is activated by PROP in vitro, this suggests an unmeasured causal SNP may be in LD with the *TAS2R4* haplotype described here. Additionally, the *TAS2R4*-allele-associated differences in the PROP responses may be due to differences in receptor expression (i.e., mRNA levels), as is known to occur for *TAS2R38* [74]. As for *TAS2R38*, our data are highly consistent with prior reports, explaining ~30% of the variation in the bitterness ratings of PROP here. Initially, we had hypothesized that the *TAS2R4* SNPs would explain the additional variance in the PROP bitterness in the AVI/AVI homozygotes. However, a model testing the effects of the *TAS2R38* diplotype and *TAS2R4* diplotype simultaneously did not show evidence to support this. The simplest explanation for this would be a lack of power for such a subgroup analysis (i.e., the AVI/AVI and SLN/SLN group only has four individuals). Alternatively, however, these two genes are in a similar region of chromosome 7, so it is possible their alleles are partially coinherited despite the absence of strong linkage disequilibrium in Figure 1. Such a relationship might be expected if they are under the same selective pressure. Accordingly, further work with larger cohorts is warranted to see if *TAS2R4* SNPs might explain the phenotypic functional recovery observed in some AVI homozygotes but not others.

While the genotypes for both *TAS2R4* and *TAS2R38* each explain a significant amount of variation in the bitterness response to PROP, the *TAS2R38* effects are predominate, explaining 29.3% of the phenotypic variance, as compared to 7.7% for the *TAS2R4* diplotype at the highest concentration. Still, the present data indicate that the polymorphisms unrelated to the well-known SNPs in *TAS2R38* also explain the variation in the suprathreshold bitterness of PROP. These data show that when considering the genetic influences on a phenotype, it is important to take into account that there may be additional receptors and polymorphisms that influence taste perception. Specifically, the data reported here suggest that the widely studied *TAS2R38* polymorphisms are not the only *TAS2R* SNPs responsible for the variation in the PROP bitterness ratings. When considering PROP phenotypes or measuring the *TAS2R38* genotype, it is not necessary to determine the *TAS2R4* genotype; however, it is important to keep in mind that *TAS2R38* is not the sole receptor for propylthiouracil. Other factors likely influence PROP perception, as *TAS2R38* haplotypes only explain a portion of the PROP variability [22]. Factors that have been previously associated with variation in PROP bitterness include mRNA expression [74] and fungiform papillae density [19,53,75,76]. Regarding food choice and food intake, a second receptor that recovers function for thiourea compounds in some AVI homozygotes may potentially explain the conflicting reports in the literature on associations between *TAS2R38* diplotypes and vegetable intake (cf. [20,41]). That is, some AVI homozygotes may behave more like

heterozygotes or PAV homozygotes in terms of diet if they also have a *TAS2R4* diplotype that makes them sensitive to vegetable bitterness.

5. Conclusions

In sum, the *TAS2R38* diplotype has consistently and repeatedly been shown to predict PROP bitterness *in vivo*, suggesting PAV homozygotes and heterozygotes have a functional receptor that causes them to perceive PROP as bitter. Further, it is widely assumed that AVI homozygotes have some degree of altered receptor function, as other data indicate that the *TAS2R38*-AVI variant is not activated by PROP or PTC *in vitro*. Despite that, many research teams have repeatedly demonstrated that many (but not all) AVI homozygotes still experience and report mild bitterness of concentrated PROP. The present data strongly implicate *TAS2R4* as a functional PROP receptor, in agreement with prior speculation on the existence of a second lower affinity PROP receptor [53]. Polymorphisms in *TAS2R4* have previously been linked to the differential bitterness of coffee and stevia plant extracts, but it remains unknown whether these same polymorphisms are predictive of dietary intake, especially in relation to vegetables and/or alcohol.

Author Contributions: Conceptualization, A.A.N. and J.E.H.; methodology, A.A.N., J.E.H. and M.B.; formal analysis, A.A.N. and M.B.; investigation, A.A.N. and M.B.; resources, J.E.H., J.E.M. and W.M.; data curation, A.A.N. and M.B.; writing—original draft preparation, A.A.N. and J.E.H.; writing—review and editing, all authors; visualization, A.A.N. and M.B.; supervision, J.E.H. and W.M.; project administration, J.E.H., M.B. and W.M.; funding acquisition, J.E.H., J.E.M. and W.M. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by a National Institutes of Health grant from the National Institute of Deafness and Communication Disorders [DC010904] to J.E.H.; United States Department of Agriculture Hatch Project PEN04332 funds (J.E.H.); Pennsylvania State University funds (J.E.H.); shared equipment grants (ShEEP) from the Medical Research Service of the Department of Veteran Affairs (J.E.M.); and a grant from the Deutsche Forschungsgemeinschaft WM (Me 1024/2-3).

Institutional Review Board Statement: This study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of the Pennsylvania State University (protocol code #33176, approval date 21 September 2011).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Data are not available, as the consent documents did not ask participants about resharing these data.

Acknowledgments: We wish to thank Emma Feeney, Nadia Byrnes, and Meghan Kane for collecting the psychophysical data, Samantha Bennett for the assistance with protocol development, Kayla Beaucage for genotyping our DNA samples, and Ulrike Redel for the *in vitro* assays. We also thank our study participants for their time and participation.

Conflicts of Interest: A.A.N., J.E.M. and J.E.H. have no conflict of interest to declare. W.M. and M.B. have filed patents and patent applications on human bitter taste receptors. The funders had no role in the design of the study; in the collection, analyses, or interpretation of the data; in the writing of the manuscript; or in the decision to publish the results.

References

1. Drewnowski, A.; Gomez-Carneros, C. Bitter taste, phytonutrients, and the consumer: A review. *Am. J. Clin. Nutr.* **2000**, *72*, 1424–1435. [[CrossRef](#)]
2. Lindemann, B. Taste reception. *Physiol. Rev.* **1996**, *76*, 719–766. [[CrossRef](#)] [[PubMed](#)]
3. Wooding, S. Signatures of natural selection in a primate bitter taste receptor. *J. Mol. Evol.* **2011**, *73*, 257–265. [[CrossRef](#)]
4. Glendinning, J.I. Is the bitter rejection response always adaptive? *Physiol. Behav.* **1994**, *56*, 1217–1227. [[CrossRef](#)]
5. Nissim, I.; Dagan-Wiener, A.; Niv, M.Y. The taste of toxicity: A quantitative analysis of bitter and toxic molecules. *IUBMB Life* **2017**, *69*, 938–946. [[CrossRef](#)] [[PubMed](#)]
6. Meyerhof, W.; Batram, C.; Kuhn, C.; Brockhoff, A.; Chudoba, E.; Bufe, B.; Appendino, G.; Behrens, M. The molecular receptive ranges of human TAS2R bitter taste receptors. *Chem. Senses* **2010**, *35*, 157–170. [[CrossRef](#)]

7. Lang, T.; Di Pizio, A.; Risso, D.; Drayna, D.; Behrens, M. Activation Profile of TAS2R2, the 26th Human Bitter Taste Receptor. *Mol. Nutr. Food Res.* **2023**, *67*, e2200775. [[CrossRef](#)] [[PubMed](#)]
8. Glendinning, J.I. What Does the Taste System Tell Us about the Nutritional Composition and Toxicity of Foods? In *The Pharmacology of Taste*; Palmer, R.K., Servant, G., Eds.; Springer International Publishing: Cham, Switzerland, 2022; pp. 321–351.
9. Hayes, J.E. Influence of sensation and liking on eating and drinking. In *Handbook of Eating and Drinking: Interdisciplinary Perspectives*; Springer: Berlin/Heidelberg, Germany, 2020; pp. 131–155. [[CrossRef](#)]
10. Kamerud, J.K.; Delwiche, J.F. Individual Differences in Perceived Bitterness Predict Liking of Sweeteners. *Chem. Senses* **2007**, *32*, 803–810. [[CrossRef](#)]
11. Hayes, J.E.; Wallace, M.R.; Knopik, V.S.; Herbstman, D.M.; Bartoshuk, L.M.; Duffy, V.B. Allelic variation in TAS2R bitter receptor genes associates with variation in sensations from and ingestive behaviors toward common bitter beverages in adults. *Chem. Senses* **2011**, *36*, 311–319. [[CrossRef](#)]
12. Kim, U.; Wooding, S.; Ricci, D.; Jorde, L.B.; Drayna, D. Worldwide haplotype diversity and coding sequence variation at human bitter taste receptor loci. *Hum. Mutat.* **2005**, *26*, 199–204. [[CrossRef](#)]
13. Roudnitzky, N.; Bufe, B.; Thalmann, S.; Kuhn, C.; Gunn, H.C.; Xing, C.; Crider, B.P.; Behrens, M.; Meyerhof, W.; Wooding, S.P. Genomic, genetic and functional dissection of bitter taste responses to artificial sweeteners. *Hum. Mol. Genet.* **2011**, *20*, 3437–3449. [[CrossRef](#)] [[PubMed](#)]
14. Dotson, C.D.; Zhang, L.; Xu, H.; Shin, Y.K.; Vignes, S.; Ott, S.H.; Elson, A.E.T.; Choi, H.J.; Shaw, H.; Egan, J.M. Bitter taste receptors influence glucose homeostasis. *PLoS ONE* **2008**, *3*, e3974. [[CrossRef](#)] [[PubMed](#)]
15. Bufe, B.; Breslin, P.A.; Kuhn, C.; Reed, D.R.; Tharp, C.D.; Slack, J.P.; Kim, U.K.; Drayna, D.; Meyerhof, W. The molecular basis of individual differences in phenylthiocarbamide and propylthiouracil bitterness perception. *Curr. Biol.* **2005**, *15*, 322–327. [[CrossRef](#)] [[PubMed](#)]
16. Pronin, A.N.; Xu, H.; Tang, H.; Zhang, L.; Li, Q.; Li, X. Specific alleles of bitter receptor genes influence human sensitivity to the bitterness of aloin and saccharin. *Curr. Biol.* **2007**, *17*, 1403–1408. [[CrossRef](#)] [[PubMed](#)]
17. Soranzo, N.; Bufe, B.; Sabeti, P.C.; Wilson, J.F.; Weale, M.E.; Marguerie, R.; Meyerhof, W.; Goldstein, D.B. Positive selection on a high-sensitivity allele of the human bitter-taste receptor TAS2R16. *Curr. Biol.* **2005**, *15*, 1257–1265. [[CrossRef](#)] [[PubMed](#)]
18. Dotson, C.D.; Wallace, M.R.; Bartoshuk, L.M.; Logan, H.L. Variation in the Gene TAS2R13 is Associated with Differences in Alcohol Consumption in Patients with Head and Neck Cancer. *Chem. Senses* **2012**, *37*, 737–744. [[CrossRef](#)] [[PubMed](#)]
19. Duffy, V.B.; Davidson, A.C.; Kidd, J.R.; Kidd, K.K.; Speed, W.C.; Pakstis, A.J.; Reed, D.R.; Snyder, D.J.; Bartoshuk, L.M. Bitter Receptor Gene (TAS2R38), 6-n-Propylthiouracil (PROP) Bitterness and Alcohol Intake. *Alcohol. Clin. Exp. Res.* **2004**, *28*, 1629–1637. [[CrossRef](#)] [[PubMed](#)]
20. Duffy, V.B.; Hayes, J.E.; Davidson, A.C.; Kidd, J.R.; Kidd, K.K.; Bartoshuk, L.M. Vegetable intake in college-aged adults is explained by oral sensory phenotypes and TAS2R38 genotype. *Chemosens. Percept.* **2010**, *3*, 137–148. [[CrossRef](#)]
21. Allen, A.L.; McGeary, J.E.; Knopik, V.S.; Hayes, J.E. Bitterness of the Non-nutritive Sweetener Acesulfame Potassium Varies With Polymorphisms in TAS2R9 and TAS2R31. *Chem. Senses* **2013**, *38*, 379–389. [[CrossRef](#)]
22. Kim, U.; Jorgenson, E.; Coon, H.; Leppert, M.; Risch, N.; Drayna, D. Positional cloning of the human quantitative trait locus underlying taste sensitivity to phenylthiocarbamide. *Sci. STKE* **2003**, *299*, 1221. [[CrossRef](#)]
23. Hinrichs, A.L.; Wang, J.C.; Bufe, B.; Kwon, J.M.; Budde, J.; Allen, R.; Bertelsen, S.; Evans, W.; Dick, D.; Rice, J. Functional Variant in a Bitter-Taste Receptor (*hTAS2R16*) Influences Risk of Alcohol Dependence. *Am. J. Hum. Genet.* **2006**, *78*, 103–111. [[CrossRef](#)] [[PubMed](#)]
24. Reed, D.R.; Zhu, G.; Breslin, P.A.S.; Duke, F.F.; Henders, A.K.; Campbell, M.J.; Montgomery, G.W.; Medland, S.E.; Martin, N.G.; Wright, M.J. The perception of quinine taste intensity is associated with common genetic variants in a bitter receptor cluster on chromosome 12. *Hum. Mol. Genet.* **2010**, *19*, 4278–4285. [[CrossRef](#)]
25. Wang, J.C.; Hinrichs, A.L.; Bertelsen, S.; Stock, H.; Budde, J.P.; Dick, D.M.; Bucholz, K.K.; Rice, J.; Saccone, N.; Edenberg, H.J. Functional Variants in TAS2R38 and TAS2R16 Influence Alcohol Consumption in High-Risk Families of African-American Origin. *Alcohol. Clin. Exp. Res.* **2007**, *31*, 209–215. [[CrossRef](#)] [[PubMed](#)]
26. Mennella, J.A.; Pepino, M.Y.; Reed, D.R. Genetic and environmental determinants of bitter perception and sweet preferences. *Pediatrics* **2005**, *115*, e216–e222. [[CrossRef](#)] [[PubMed](#)]
27. Pawellek, I.; Grote, V.; Rzehak, P.; Xhonneux, A.; Verduci, E.; Stolarczyk, A.; Closa-Monasterolo, R.; Reischl, E.; Koletzko, B.; European Childhood Obesity Trial Study Group. Association of TAS2R38 variants with sweet food intake in children aged 1–6 years. *Appetite* **2016**, *107*, 126–134. [[CrossRef](#)] [[PubMed](#)]
28. Bobowski, N.; Reed, D.R.; Mennella, J.A. Variation in the TAS2R31 bitter taste receptor gene relates to liking for the nonnutritive sweetener Acesulfame-K among children and adults. *Sci. Rep.* **2016**, *6*, 39135. [[CrossRef](#)] [[PubMed](#)]
29. Barajas-Ramirez, J.A.; Quintana-Castro, R.; Oliart-Ros, R.M.; Angulo-Guerrero, O. Bitter taste perception and TAS2R38 genotype: Effects on taste sensitivity, food consumption and anthropometry in Mexican adults. *Flavour. Fragr. J.* **2016**, *31*, 310–318. [[CrossRef](#)]
30. Hayes, J.E.; Nolden, A.A. Biologically driven differences in sensation: Implications for the wine industry. In Proceedings of the 16th Australian Wine Industry Technical Conference, Adelaide, Australia, 24–28 July 2016.
31. Beckett, E.L.; Duesing, K.; Boyd, L.; Yates, Z.; Veysey, M.; Lucock, M. A potential sex dimorphism in the relationship between bitter taste and alcohol consumption. *Food Funct.* **2017**, *8*, 1116–1123. [[CrossRef](#)] [[PubMed](#)]

32. Perna, S.; Riva, A.; Nicosanti, G.; Carrai, M.; Barale, R.; Vigo, B.; Allegrini, P.; Rondanelli, M. Association of the bitter taste receptor gene TAS2R38 (polymorphism RS713598) with sensory responsiveness, food preferences, biochemical parameters and body-composition markers. A cross-sectional study in Italy. *Int. J. Food Sci. Nutr.* **2018**, *69*, 245–252. [[CrossRef](#)]
33. Meng, T.; Nielsen, D.E. An Investigation of TAS2R38 Haplotypes, Dietary Intake, and Risk Factors for Chronic Disease in the Canadian Longitudinal Study on Aging. *J. Nutr.* **2023**, *153*, 3270–3279. [[CrossRef](#)]
34. Smith, J.L.; Estus, S.; Lennie, T.A.; Moser, D.K.; Chung, M.L.; Mudd-Martin, G. TAS2R38 PAV Haplotype Predicts Vegetable Consumption in Community-Dwelling Caucasian Adults at Risk for Cardiovascular Disease. *Biol. Res. Nurs.* **2020**, *22*, 326–333. [[CrossRef](#)] [[PubMed](#)]
35. Sandell, M.; Hoppu, U.; Mikkilä, V.; Mononen, N.; Kahonen, M.; Mannisto, S.; Ronnema, T.; Viikari, J.; Lehtimäki, T.; Raitakari, O.T. Genetic variation in the hTAS2R38 taste receptor and food consumption among Finnish adults. *Genes Nutr.* **2014**, *9*, 433. [[CrossRef](#)] [[PubMed](#)]
36. Sandell, M.A.; Breslin, P.A. Variability in a taste-receptor gene determines whether we taste toxins in food. *Curr. Biol.* **2006**, *16*, R792–R794. [[CrossRef](#)] [[PubMed](#)]
37. Shen, Y.; Kennedy, O.B.; Methven, L. Exploring the effects of genotypical and phenotypical variations in bitter taste sensitivity on perception, liking and intake of brassica vegetables in the UK. *Food Qual. Prefer.* **2016**, *in press*. [[CrossRef](#)]
38. Timpson, N.J.; Christensen, M.; Lawlor, D.A.; Gaunt, T.R.; Day, I.N.; Smith, G.D. TAS2R38 (phenylthiocarbamide) haplotypes, coronary heart disease traits, and eating behavior in the British Women’s Heart and Health Study. *Am. J. Clin. Nutr.* **2005**, *81*, 1005–1011. [[CrossRef](#)] [[PubMed](#)]
39. Calancie, L.; Keyserling, T.C.; Taillie, L.S.; Robasky, K.; Patterson, C.; Ammerman, A.S.; Schisler, J.C. TAS2R38 Predisposition to Bitter Taste Associated with Differential Changes in Vegetable Intake in Response to a Community-Based Dietary Intervention. *G3 Genes Genomes Genet.* **2018**, *8*, 2107–2119. [[CrossRef](#)] [[PubMed](#)]
40. Mikolajczyk-Stecyna, J.; Malinowska, A.M.; Chmurzynska, A. TAS2R38 and CA6 genetic polymorphisms, frequency of bitter food intake, and blood biomarkers among elderly woman. *Appetite* **2017**, *116*, 57–64. [[CrossRef](#)] [[PubMed](#)]
41. O’Brien, S.A.; Feeney, E.L.; Scannell, A.G.; Markey, A.; Gibney, E.R. Bitter taste perception and dietary intake patterns in Irish children. *J. Nutr. Nutr.* **2013**, *6*, 43–58. [[CrossRef](#)]
42. Hejazi, J.; Amiri, R.; Nozarian, S.; Tavasolian, R.; Rahimlou, M. Genetic determinants of food preferences: A systematic review of observational studies. *BMC Nutr.* **2024**, *10*, 24. [[CrossRef](#)]
43. Diószegi, J.; Llanaj, E.; Ádány, R. Genetic Background of Taste Perception, Taste Preferences, and Its Nutritional Implications: A Systematic Review. *Front. Genet.* **2019**, *10*, 1272. [[CrossRef](#)]
44. Fox, A. Six in ten ‘tastebblind’ to bitter chemical. *Sci. News Lett.* **1931**, *9*, 249.
45. Fox, A.L. The relationship between chemical constitution and taste. *Proc. Natl. Acad. Sci. USA* **1932**, *18*, 115. [[CrossRef](#)]
46. Fischer, R.; Griffin, F.; England, S.; Garn, S.M. Taste thresholds and food dislikes. *Nature* **1961**, *191*, 1328. [[CrossRef](#)]
47. Fischer, R.; Griffin, F.; Kaplan, A.R. Taste Thresholds, Cigarette Smoking, and Food Dislikes. *Med. Exp. Int. J. Exp. Med.* **1963**, *210*, 151–167. [[CrossRef](#)] [[PubMed](#)]
48. Glanville, E.V.; Kaplan, A.R. Food Preference and Sensitivity of Taste for Bitter Compounds. *Nature* **1965**, *205*, 851–853. [[CrossRef](#)]
49. Wooding, S. Phenylthiocarbamide: A 75-year adventure in genetics and natural selection. *Genetics* **2006**, *172*, 2015–2023. [[CrossRef](#)] [[PubMed](#)]
50. Blakeslee, A.F. Genetics of sensory thresholds: Taste for phenyl thio carbamide. *Proc. Natl. Acad. Sci. USA* **1932**, *18*, 120–130. [[CrossRef](#)]
51. Newcomb, R.; Xia, M.; Reed, D. Heritable differences in chemosensory ability among humans. *Flavour* **2012**, *1*, 9. [[CrossRef](#)]
52. Guo, S.W.; Reed, D.R. The genetics of phenylthiocarbamide perception. *Ann. Hum. Biol.* **2001**, *28*, 111–142.
53. Hayes, J.E.; Bartoshuk, L.M.; Kidd, J.R.; Duffy, V.B. Supertasting and PROP Bitterness Depends on More Than the TAS2R38 Gene. *Chem. Senses* **2008**, *33*, 255–265. [[CrossRef](#)]
54. Behrens, M.; Gunn, H.C.; Ramos, P.C.M.; Meyerhof, W.; Wooding, S.P. Genetic, Functional, and Phenotypic Diversity in TAS2R38-Mediated Bitter Taste Perception. *Chem. Senses* **2013**, *38*, 475–484. [[CrossRef](#)] [[PubMed](#)]
55. Wooding, S.; Gunn, H.; Ramos, P.; Thalmann, S.; Xing, C.; Meyerhof, W. Genetics and bitter taste responses to goitrin, a plant toxin found in vegetables. *Chem. Senses* **2010**, *35*, 685–692. [[CrossRef](#)] [[PubMed](#)]
56. Aoki, K.; Mori, K.; Iijima, S.; Sakon, M.; Matsuura, N.; Kobayashi, T.; Takanashi, M.; Yoshimura, T.; Mori, N.; Katayama, T. Association between Genetic Variation in the TAS2R38 Bitter Taste Receptor and Propylthiouracil Bitter Taste Thresholds among Adults Living in Japan Using the Modified 2AFC Procedure with the Quest Method. *Nutrients* **2023**, *15*, 2415. [[CrossRef](#)] [[PubMed](#)]
57. Duffy, V.B.; Peterson, J.; Bartoshuk, L.M. Associations between taste genetics, oral sensations and alcohol intake. *Physiol. Behav.* **2004**, *82*, 435–445. [[CrossRef](#)] [[PubMed](#)]
58. Nolden, A.A.; Hayes, J.E.; Feeney, E.L. Variation in TAS2R receptor genes explains differential bitterness of two common antibiotics. *Front. Genet.* **2022**, *13*, 960154. [[CrossRef](#)] [[PubMed](#)]
59. Webb, J.; Bolhuis, D.P.; Cicerale, S.; Hayes, J.E.; Keast, R. The Relationships Between Common Measurements of Taste Function. *Chemosens. Percept.* **2015**, *8*, 11–18. [[CrossRef](#)] [[PubMed](#)]
60. Hayes, J.E.; Feeney, E.L.; Nolden, A.A.; McGeary, J.E. Quinine Bitterness and Grapefruit Liking Associate with Allelic Variants in TAS2R31. *Chem. Senses* **2015**, *40*, 437–443. [[CrossRef](#)] [[PubMed](#)]

61. Chandrashekar, J.; Mueller, K.L.; Hoon, M.A.; Adler, E.; Feng, L.; Guo, W.; Zuker, C.S.; Ryba, N.J.P. T2Rs function as bitter taste receptors. *Cell* **2000**, *100*, 703–711. [[CrossRef](#)] [[PubMed](#)]
62. Meyerhof, W. Elucidation of mammalian bitter taste. In *Reviews of Physiology, Biochemistry and Pharmacology*; Springer: Berlin/Heidelberg, Germany, 2005; pp. 37–72.
63. Soares, S.; Kohl, S.; Thalmann, S.; Mateus, N.; Meyerhof, W.; De Freitas, V. Different Phenolic Compounds Activate Distinct Human Bitter Taste Receptors. *J. Agric. Food Chem.* **2013**, *61*, 1525–1533. [[CrossRef](#)]
64. Maehashi, K.; Matano, M.; Wang, H.; Vo, L.A.; Yamamoto, Y.; Huang, L. Bitter peptides activate hTAS2Rs, the human bitter receptors. *Biochem. Biophys. Res. Commun.* **2008**, *365*, 851–855. [[CrossRef](#)]
65. Kohl, S.; Behrens, M.; Dunkel, A.; Hofmann, T.; Meyerhof, W. Amino Acids and Peptides Activate at Least Five Members of the Human Bitter Taste Receptor Family. *J. Agric. Food Chem.* **2013**, *61*, 53–60. [[CrossRef](#)] [[PubMed](#)]
66. Risso, D.; Morini, G.; Pagani, L.; Quagliarello, A.; Giuliani, C.; De Fanti, S.; Sazzini, M.; Luiselli, D.; Tofanelli, S. Genetic signature of differential sensitivity to stevioside in the Italian population. *Genes Nutr.* **2014**, *9*, 401. [[CrossRef](#)] [[PubMed](#)]
67. Feeney, E.L.; Hayes, J.E. Regional differences in suprathreshold intensity for bitter and umami stimuli. *Chemosens. Percept.* **2014**, *7*, 147–157. [[CrossRef](#)] [[PubMed](#)]
68. Hayes, J.E.; Allen, A.L.; Bennett, S.M. Direct comparison of the generalized Visual Analog Scale (gVAS) and general Labeled Magnitude Scale (gLMS). *Food Qual. Prefer.* **2013**, *28*, 36–44. [[CrossRef](#)]
69. Snyder, D.; Fast, K. Valid comparisons of suprathreshold sensations. *J. Conscious. Stud.* **2004**, *11*, 96–112.
70. Hayes, J.E.; Duffy, V.B. Revisiting sugar-fat mixtures: Sweetness and creaminess vary with phenotypic markers of oral sensation. *Chem. Senses* **2007**, *32*, 225–236. [[CrossRef](#)] [[PubMed](#)]
71. Floriano, W.B.; Hall, S.; Vaidehi, N.; Kim, U.; Drayna, D.; Goddard, W.A., 3rd. Modeling the human PTC bitter-taste receptor interactions with bitter tastants. *J. Mol. Model.* **2006**, *12*, 931–941. [[CrossRef](#)] [[PubMed](#)]
72. Robino, A.; Concas, M.P.; Spinelli, S.; Pierguidi, L.; Tepper, B.J.; Gasparini, P.; Prescott, J.; Monteleone, E.; Toschi, T.G.; Torri, L.; et al. Combined influence of TAS2R38 genotype and PROP phenotype on the intensity of basic tastes, astringency and pungency in the Italian taste project. *Food Qual. Prefer.* **2022**, *95*, 104361. [[CrossRef](#)]
73. Reed, D.; Mascioli, K.; Obenrader, S.; Bartoshuk, L.; Duffy, V. Human PROP Insensitivity is not accounted for by single nucleotide polymorphisms in the putative bitter receptors TAS2R3, TAS2R4, and TAS2R5. *Chem. Senses* **2002**, *28*, 75. [[CrossRef](#)]
74. Lipchock, S.V.; Mennella, J.A.; Spielman, A.I.; Reed, D.R. Human bitter perception correlates with bitter receptor messenger RNA expression in taste cells. *Am. J. Clin. Nutr.* **2013**, *98*, 1136–1143. [[CrossRef](#)]
75. Miller, I.J.; Reedy, F.E. Variations in Human Taste Bud Density and Taste Intensity Perception. *Physiol. Behav.* **1990**, *47*, 1213–1219. [[CrossRef](#)] [[PubMed](#)]
76. Bartoshuk, L.M.; Duffy, V.B.; Miller, I.J. PTC/PROP tasting: Anatomy, psychophysics, and sex effects. *Physiol. Behav.* **1994**, *56*, 1165–1171. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.